Abstract: The present invention provides a method for producing a heart organoid and/or a lung organoid, comprising the step of: culturing an embryoid body in the presence of an FGF protein on a surface of a gel containing an extracellular matrix constituent protein.
Type:
Application
Filed:
September 28, 2018
Publication date:
September 10, 2020
Applicant:
National University Corporation Tokyo Medical and Dental University
Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.
Type:
Grant
Filed:
August 8, 2017
Date of Patent:
August 4, 2020
Assignee:
National University Corporation Tokyo Medical and Dental University
Abstract: An objective of the present invention is to provide a biomagnetism measurement device capable of three-dimensionally acquiring magnetism information of a living body with ease. This biomagnetism measurement device (101) is for measuring biomagnetism using a plurality of magnetic sensors (1) at the same time. The plurality of magnetic sensors (1) is retained by a retaining part (100) (a first retaining portion [11] and a second retaining portion [12]) so as to have different measurement directions. Furthermore, the retaining part (10) (the first retaining portion [11] and the second retaining portion [12]) has arranged thereon the plurality of magnetic sensors (1) so as to enable biomagnetism to be measured at a plurality of sites at the same time. The magnetic sensor (1) comprises a means for detecting the biomagnetism in a temperature environment commensurate with normal temperature.
Type:
Application
Filed:
August 21, 2018
Publication date:
July 30, 2020
Applicants:
National University Corporation Tokyo Medical and Dental University, TDK CORPORATION
Abstract: A nerve stimulation apparatus is provided. The nerve stimulation apparatus detects nerve activities from a body surface and applies stimulation. The nerve stimulation apparatus includes a stimulation apparatus with multiple electrodes which are arranged on skin and a current supply unit which supplies a current to the electrodes, which stimulation apparatus provides the current to a living body percutaneously to stimulate a target nerve; a measurement apparatus which measures activities of muscles governed by the nerve according to the stimulation from the stimulation apparatus; and an information processing apparatus which determines, based on a measurement result of the nerve activities obtained from the measurement apparatus, which electrode is capable of providing the target nerve activities equal to or greater than a desired value.
Type:
Grant
Filed:
November 7, 2016
Date of Patent:
July 28, 2020
Assignees:
Ricoh Company, Ltd., National University Corporation Tokyo Medical and Dental University
Abstract: The present invention provides novel compositions for suppressing or improving hair loss, and compositions for suppressing or improving graying. More specifically, it provides agents that stabilize type XVII collagen expression, preferably agents that suppress the degradation of type XVII collagen by ELANE inhibitors and such, and compositions comprising a DNA repair-promoting agent or a DNA damage-suppressing agent as an active ingredient. Advantageous suppressive effects of hair loss and graying can be obtained when a composition comprising as an active ingredient a suppressive agent of type XVII collagen degradation such as an ELANE inhibitor is administered to a mammal. For the ELANE inhibitors, suppressive agents of type XVII collagen degradation and DNA repair-promoting agents, low-molecular compounds, polypeptides, proteins, antibodies, or nucleic acid medicine such as antisense oligos or siRNAs may be used.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
July 7, 2020
Assignee:
National University Corporation Tokyo Medical and Dental University
Abstract: The present invention provides a coronary artery bypass surgery treatment tool or the like including a flexible tube, a suction cup in which an opening portion is formed to communicate with the flexible tube and which is provided at a distal end of the flexible tube, a joint portion which has a suction path, a male connector which is provided in one of a proximal end of the flexible tube and a distal end of the suction path of the joint portion, and a female connector which is provided in the other thereof and is detachably connected to the male connector.
Type:
Application
Filed:
May 16, 2018
Publication date:
June 25, 2020
Applicants:
SUMITOMO BAKELITE CO., LTD., NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Abstract: A modified nanoparticle includes a nanoparticle, a dispersibility improving group bound to a surface of the nanoparticle, and an oligosaccharide that is bound to the surface of the nanoparticle, and that selectively captures a specific virus or bacterium. A reagent for detection of a specific virus or bacterium by resistive pulse sensing is also provided, the reagent including the modified nanoparticle.
Type:
Application
Filed:
April 25, 2018
Publication date:
May 28, 2020
Applicant:
National University Corporation Tokyo Medical and Dental University
Abstract: An alloy for biomedical use includes Zr as a main component, Nb the content of which is not less than 0.1% by weight and not greater than 25% by weight, Mo the content of which is not less than 0.1% by weight and not greater than 25% by weight, and Ta the content of which is not less than 0.1% by weight and not greater than 25% by weight. A tensile strength of the alloy is not less than 1000 MPa. A total content of Nb, Mo, and Ta in the alloy is not less than 2% by weight and not greater than 50% by weight. Mass susceptibility of the alloy is not greater than 1.50×10?6 cm3/g. A Young's modulus of the alloy is not greater than 100 GPa. Also disclosed is a medical product including the alloy and a method for producing the alloy.
Type:
Application
Filed:
July 24, 2018
Publication date:
May 21, 2020
Applicants:
TOKUSEN KOGYO CO., LTD, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Abstract: The invention provides a novel myogenesis promotor, a novel muscle atrophy inhibitor, a novel composition or a novel TAZ activator. The myogenesis promotor, the muscle atrophy inhibitor, the composition and the TAZ activator include a composition represented by the following Formula (I) as an active ingredient. In Formula (I), R1 represents a hydrogen atom or an alkyl group; R2 represents an aryl group, a heterocyclic group, an alkyl group or the like; R3 represents —NR5R6 or —N?C—R7; each of R5 and R6 independently represents a hydrogen atom, an alkyl group or the like; R7 represents —NR10R11, an aryl group or a heterocyclic group; R8 represents a hydrogen atom, an alkyl group or the like; R9 represents a hydrogen atom, an alkyl group or the like; each of R10 and R11 independently represents a hydrogen atom, an alkyl group or the like; R4 represents a cyano group or —C(?O)R12; and R12 represents an aryl group, a heterocyclic group, an alkyl group or the like.
Type:
Grant
Filed:
February 6, 2015
Date of Patent:
May 19, 2020
Assignee:
National University Corporation Tokyo Medical and Dental University
Inventors:
Yutaka Hata, Hiroyuki Kagechika, Kentaro Nakagawa, Shigeru Ito
Abstract: An object of the present invention is to provide a detection method for Mycoplasma by which a greater number of Mycoplasma species can be more quickly and easily detected with high sensitivity and accuracy, a set of a forward primer, a reverse primer and a probe for the detection and a kit containing the set.
Type:
Grant
Filed:
September 7, 2015
Date of Patent:
May 5, 2020
Assignees:
National University Corporation Tokyo Medical and Dental University, Lymphotec Inc.
Abstract: Provided is a nucleic acid inhibiting a function of a target miRNA. Provided is a double-stranded nucleic acid complex comprising a first nucleic acid strand of 6 to 30 nucleotide length that hybridizes to a target miRNA to inhibit a function of the target miRNA, and a second nucleic acid strand complementary to the first nucleic acid strand, wherein the first nucleic acid strand is a mixmer comprising a natural nucleoside and a non-natural nucleoside, and the second nucleic acid strand comprises at least one of one or more modified internucleoside linkages and one or more sugar modified nucleosides.
Type:
Application
Filed:
June 29, 2018
Publication date:
April 16, 2020
Applicant:
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Abstract: A material for treatment of brain injury, a method for treatment of brain injury, a material for regeneration of brain neurons, and a method for regeneration of brain neurons are provided. The material for treatment of brain injury contains a carrier on which at least one selected from the group consisting of N-cadherin, a fusion protein containing an entire or partial region of N-cadherin, and a fusion protein containing an entire or partial region of a protein having homology to N-cadherin is immobilized or coated.
Type:
Application
Filed:
June 28, 2019
Publication date:
February 6, 2020
Applicants:
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, SOMAR CORPORATION
Abstract: A wireless biological signal communication terminal is provided with: a sensor unit which detects a biological signal; an A/D converting unit which performs A/D conversion of the biological signal in accordance with a set sampling frequency to obtain biological signal data; a recording unit which records a plurality of items of A/D converted biological signal data; a control unit which processes the plurality of items of biological signal data recorded by the recording unit in a prescribed period of time; a wireless module unit and an antenna which wirelessly transmit the result of the processing performed by the control unit to an external device; and a power supply unit which supplies power to drive the devices.
Type:
Application
Filed:
September 22, 2017
Publication date:
January 23, 2020
Applicants:
National University Corporation Tokyo Medical and Dental University, TDK CORPORATION
Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.
Type:
Application
Filed:
January 7, 2019
Publication date:
December 5, 2019
Applicant:
National University Corporation Tokyo Medical and Dental University
Abstract: A pharmaceutical composition for neovascular diseases, a pharmaceutical composition for inhibiting an angiogenic growth factor, and use of these pharmaceutical compositions are provided. In one or more embodiments, a pharmaceutical composition contains as an active ingredient a low molecular weight compound that is able to suppress the expression of VEGF gene in cells or to reduce the production of VEGF protein from cells. In one or more embodiments, a pharmaceutical composition contains as an active ingredient a compound expressed by the following formula (I) or a prodrug thereof or pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
February 25, 2019
Publication date:
December 5, 2019
Applicants:
KYOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Inventors:
Masatoshi HAGIWARA, Satoshi MOROOKA, Takamitsu HOSOYA, Suguru YOSHIDA
Abstract: An object of the present invention is to provide a preservative solution for human stem cells, a human stem cell suspension, and a method for preserving human stem cells, which enable preservation of human stem cells at a high survival rate for cells. According to the present invention, a preservative solution for human stem cells is provided. The preservative solution includes at least human serum, in which a volume ratio of human serum with respect to the entire preservative solution is 0.70 or more, and the human stem cells are preserved at a temperature higher than 0° C.
Type:
Application
Filed:
August 9, 2019
Publication date:
November 28, 2019
Applicants:
FUJIFILM Corporation, National University Corporation Tokyo Medical and Dental University
Abstract: A method comprises obtaining a first cell image of a cell by a first observation method, obtaining a second cell image of the cell by a second observation method that is different from the first observation method, and determining the region of the cell based on the first cell image and the second cell image.
Type:
Grant
Filed:
December 27, 2016
Date of Patent:
November 19, 2019
Assignees:
SYSMEX CORPORATION, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Abstract: A biological information measuring apparatus includes a radiation emitting unit configured to emit radiation to a subject, a biomagnetic field detector configured to detect a biomagnetic field on the subject, and a radiation sensitive material having sensitivity to the radiation, having enough size for enabling radiography of an examination target of the subject, and being nonmagnetic. The radiation sensitive material is arranged between an examination region where the examination target of the subject is to be positioned and the biomagnetic field detector.
Type:
Grant
Filed:
April 11, 2016
Date of Patent:
October 8, 2019
Assignee:
National University Corporation Tokyo Medical and Dental University
Abstract: A medicinal composition for diseases caused by dyslipidemia and/or autophagy dysfunction, etc., said medicinal composition comprising polyrotaxane that carries bulky substituents introduced, via intracellularly degradable bonds, into both ends of a linear molecule penetrating through plural cyclic molecules.
Type:
Grant
Filed:
August 18, 2014
Date of Patent:
September 10, 2019
Assignee:
National University Corporation Tokyo Medical and Dental University
Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
Type:
Application
Filed:
May 13, 2019
Publication date:
September 5, 2019
Applicants:
National University Corporation Tokyo Medical and Dental University, Osaka University